Biology · Nov 16, 2026
Hepatic Matrix Gene Expression Remains Elevated Relative to Chow-Fed References During Semaglutide Treatment in Murine MASH: Associations with Human Fibrosis Stage
By Xu Q, Li M, Fan N et al.
Semaglutide improves metabolic dysfunction-associated steatohepatitis (MASH), but the extent of hepatic transcriptional recovery remains unclear. We compared predefined program scores between semaglutide-treated and healthy groups in three GAN diet-induced MASH mouse experiments and an independent Ldlr−/−.Leiden model. We examined cross-sectional associations between corresponding human orthologs and fibrosis stage in three liver-biopsy cohorts with no semaglutide treatment comparison. Treated-minus-healthy extracellular matrix (ECM) score differences were 0.57–0.89 mean log2 units in the original experiments and 0.79 (95% confidence interval 0.62–0.97) in the independent model. Collagen scores also remained elevated. In 206 human donors, ECM and collagen scores were 0.33 (95% CI 0.23–0.44) and 0.37 (0.27–0.47) standard deviations higher per fibrosis stage, respectively, with positive associations in the other cohorts. A broader mouse-derived residual signature closely tracked the disease-associated signature and provided little additional information beyond ECM in the external test. Matrix–program expression remained elevated relative to chow-fed references under continued disease-inducing diets.